Early March will see Zimmer & Mann release the ‘Malignant Cells’ EP via his Imola Music imprint, comprising three original tracks from the German artist.
Jens Zimmerman better known as Zimmer & Mann launched the Imola imprint in 2011 and has since gone on to release material from Cadenza’s Argenis Brito, Someone Else and Extended Play. Here though we see the founder step up to deliver his own inaugural release for the label with ‘Malignant Cells’. Jens explains ‘’these tracks where created during a 1 year cancer disease & chemotherapy. The music was for me a way to psychologically process the disease and the music helped me to go through some terrible experiences. I am donating any income made from the record to the children's cancer fund.’’.
‘Signs & Symptoms’ takes the lead on the release and sees Zimmer & Mann deliver a brooding slice of dub-infused material with vacillating low-end tones, wandering arpeggios and spiralling dub stabs lying at the forefront. Up next is title ‘Malignant Cells’ which ups the energy levels fusing elevating arps with soaring leads and a driving stab sequences to create a dynamic and tension building workout.
‘Cortisone’ then rounds out the EP on a deeper tip with swirling atmospherics, elongated synth drones and square wave bass hits gradually unfolding and developing throughout the compositions seven-minute duration.
Zimmer & Mann’s ‘Malignant Cells’ EP is out on Imola Music 1st March 2016.
Tracklist:
Signs & Symptoms
Malignant Cells
Cortisone
Visionary electronic artist Chris Avantgarde has enlisted Eddie Thoneick and Kisch for his newest single…
Miami-based duo Black V Neck and live techno-house act SHADED have teamed up for a…
Ticky returns to Rabbit Hole with a new vocal link-up, joining amelie eve once again…
As 2025 draws towards its inevitable conclusion, STBAN’s FLAMENCA Records studio shows absolutely no…
REFUGE NYC closes out its inaugural year with a truly special moment: Sasha performing…
Toronto-based duo flowanastasia & Tyr Kohout return with their brand-new single ‘Charter’, out now via…